EC Number   |
Protein Variants |
Reference |
|---|
   3.4.21.B1 | E393Q |
Marburg II single nucleotide polymorphism. Is not associated with altered enzymatic activity or any other changes in FSAP function |
690121 |
| 3.4.21.B1 | G511E |
Marburg I mutant, underlies a polymorphism in the HABP2 gene, is found in 5-10% of the population. Is associated with an impaired pro-urikinase activation, and increased neointima formation correlated with reduced proteolysis of platlet derived growth factor-BB. The polymorphism is correlated with carotid stenosis and may contribute to the risk of venous thrombosis |
687108 |
| 3.4.21.B1 | G534E |
Marburg I single nucleotide polymorphism. Has a 5fold lower enzymatic activity. Is a weak activator of pro-uPA, ability to activate factor VII is unchanged. Is strongly linked to late complications of carotid stenosis, direct role in atherosclerosis, risk factor for cardiovascular disease in general, may be also associated with venous thromboembolism |
690121 |
| 3.4.21.B1 | G534E |
the naturally occurring G534E-variant exhibits reduced proteolytic activity |
692366 |
| 3.4.21.B1 | more |
fusion of a modified TSG-6 Link module with mutationally inactivated heparin-binding sequence and the Fc portion of human IgG1 (TSG-6-DELTAHep-Fc) |
731684 |
| 3.4.21.B1 | more |
the 1601GA genotype of the 1601 G/A polymorphism in the factor VII-activating protease gene expresses reduced levels of an alloenzyme with reduced pro-fibrinolytic activity. The relative increase in FSAP activity is significantly higher in women carrying the 1601GG genotype (63%) than in women carrying 1601GA genotype (50%) and is associated with an increased activation of factor VII |
718425 |
| 3.4.21.B1 | more |
the DEGF-3 mutant shows diminished binding to and activation by heparin |
692366 |
